Oncogenic HPV types not detected

From Clinical Guidelines Wiki


Guideline contents > Oncogenic HPV types not detected

  Cite this page

Canfell,K, Hammond, I, Saville,M, Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. Oncogenic HPV typesOncogenic HPV are HPV types considered capable of causing cancer. Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 are included in tests suitable for cervical screening. Some tests also detect type 66. not detected [Version URL: https://wiki.cancer.org.au/australiawiki/index.php?oldid=190200, cited 2021 Mar 6]. Available from https://wiki.cancer.org.au/australia/Clinical_question:Oncogenic_HPV_types_not_detected. In: Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia. Available from: https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.


Last modified:
15 August 2018 01:05:35

Women in whom oncogenic HPV types are not detected are at very low risk of cervical intraepithelial neoplasia grade 3 (CIN3) and cervical cancer for at least 5 years (see Chapter 2. The rationale for primary HPV screening).[1][2] MSACThe Australian Medical Services Advisory Committee recommended that these women can continue 5-yearly screening (see Medical Services Advisory Committee recommendations for HPV testing).[3]

MSACThe Australian Medical Services Advisory Committee evidence-based recommendationQuestion mark transparent.png

REC6.1: Oncogenic HPV typesOncogenic HPV are HPV types considered capable of causing cancer. Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 are included in tests suitable for cervical screening. Some tests also detect type 66. not detected at routine screening
Women who have a screening HPV test in which oncogenic HPV types are not detected should rescreen in 5 years.

Back to top

References

  1. ↑ Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011 Jul;12(7):663-72 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/21684207.
  2. ↑ Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008 Oct 13;337:a1754 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/18852164.
  3. ↑ Medical Services Advisory Committee. MSAC Outcomes. Application No. 1276 – Renewal of the National Cervical Screening Program. [homepage on the internet] Canberra: Australian Government Department of Health; 2014 [updated 2015 Apr]. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276%20-%20Final%20MSAC%20PSD%20-%20NCSP%20Renewal.pdf.

Back to top

Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Clinical_question:Oncogenic_HPV_types_not_detected&oldid=190200"